Agilent

Country: United States
Ticker: NYSE:A

Coverage

	CN	EU	IN	US
analytics-pat	✓	✓	—	✓
automation-robotics	✓	✓	—	✓
diagnostics-medtech	✓	✓	✓	✓

Regulatorsfdaemanmpa

Verifiable facts

Fact	Value	Source
Capacity	$725 million investment to double manufacturing capacity of therapeutic nucleic acids at Frederick, Colorado site	agilent.com · investor.agilent.com
Certification	ISO 13485:2016 (MDSAP) certification for various facilities including locations in the U.S., China, Singapore, and Denmark	agilent.com
Regulatory approval	Products subject to FDA and other global regulatory bodies for approval, including EU In Vitro Diagnostic Regulation compliance	marketscreener.com · sec.gov
Production site	Manufacturing facilities located in California, Colorado, Delaware, Iowa, Massachusetts, Texas, Vermont, Canada, China, Denmark, Germany, Malaysia, and Singapore	sec.gov
Headcount	Approximately 18,100 employees as of October 31, 2025	marketscreener.com · sec.gov
Revenue	$6.948 billion for the fiscal year ended October 31, 2025	marketscreener.com · sec.gov

Independent sources: marketscreener.com · sec.gov

Technologies

Name	Cluster	Risk
Breathomics	diagnostics-medtech	Medium	→
Capillary electrophoresis for biopharma	analytics-pat	Low	→
Companion diagnostics platforms	diagnostics-medtech	Low	→
Gantry robots for wet labs	automation-robotics	Low	→
HPLC/UPLC instruments for biopharma	analytics-pat	Low	→
Lab automation & liquid handling	automation-robotics	Low	→
Plate readers for bioproduction	analytics-pat	Low	→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.